Cardiff Oncology, Inc. (CRDF) Social Stream
CARDIFF ONCOLOGY INC (CRDF) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering CRDF.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-24 | 4 | $26 | $25 | $25.333 | $1.62 | 1463.77% |
| 2021-12-08 | 5 | $26 | $19 | $23.75 | $1.62 | 1366.05% |
| 2022-01-19 | 6 | $26 | $19 | $23.75 | $1.62 | 1366.05% |
| 2022-02-27 | 6 | $26 | $19 | $22.75 | $1.62 | 1304.32% |
| 2022-04-12 | 6 | $25 | $9 | $18.5 | $1.62 | 1041.98% |
| 2022-05-06 | 6 | $25 | $9 | $18.25 | $1.62 | 1026.54% |
| 2022-05-09 | 6 | $22 | $9 | $17.5 | $1.62 | 980.25% |
| 2022-05-10 | 6 | $22 | $9 | $15 | $1.62 | 825.93% |
| 2022-05-27 | 6 | $22 | $7 | $11.75 | $1.62 | 625.31% |
| 2022-08-08 | 5 | $22 | $7 | $12.666 | $1.62 | 681.85% |
| 2022-08-29 | 5 | $22 | $6 | $11.666 | $1.62 | 620.12% |
| 2022-09-13 | 5 | $22 | $5 | $11 | $1.62 | 579.01% |
| 2022-09-16 | 5 | $14 | $5 | $8.333 | $1.62 | 414.38% |
| 2023-05-05 | 5 | $15 | $5 | $8.333 | $1.62 | 414.38% |
| 2023-05-09 | 5 | $14 | $5 | $8 | $1.62 | 393.83% |
The Trend in the Analyst Price Target
CRDF's average price target has moved down $18.25 over the prior 28 months.
Over the past 50 weeks, CRDF's average upside potential has been 510.75%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-05-27 | 6 | 22 | 7 | 11.750 | 1.30 | 803.85% |
| 2022-09-13 | 5 | 22 | 5 | 11.000 | 1.89 | 482.01% |
| 2022-09-27 | 5 | 14 | 5 | 8.000 | 1.55 | 416.13% |
| 2023-03-07 | 5 | 15 | 5 | 8.333 | 1.85 | 350.43% |
| 2023-05-05 | 5 | 15 | 5 | 8.333 | 1.88 | 343.24% |
CRDF Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
CRDF's average broker recommendation rating improved by 0 over the prior 13 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CRDF as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, CARDIFF ONCOLOGY INC's upside potential (average analyst target price relative to current price) is higher than 1527.02% of them.
- To contextualize these metrics, consider that out of all US stocks, CARDIFF ONCOLOGY INC's variance in analysts' estimates is lower than -1000.92% of them.
- In terms of how CARDIFF ONCOLOGY INC fares relative to Healthcare stocks, note that its average analyst price target is greater than 464.47% of that group.
- CARDIFF ONCOLOGY INC's number of analysts covering the stock is higher than 1043.63% of stocks in the small market cap category.
In the Pharmaceutical Products industry, BCLI, CRIS, and AGEN are the three stocks most similar to CARDIFF ONCOLOGY INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for CRDF? Use POWR Ratings for clearer insight into price direction.